LCM
BIIB icon

LCM Capital Management’s Biogen BIIB Stock Holding History

LCM Capital Management’s Portfolio BIIB Stock Details BIIB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-928
Closed -$215K – 97
2024
Q2 		$215K Buy
+928
New +$202K 0.13% 83
2024
Q1 		– Sell
-924
Closed -$239K – 94
2023
Q4 		$239K Sell
924
-4
-0.4% -$982 0.17% 75
2023
Q3 		$239K Buy
928
+40
+5% +$10.7K 0.19% 75
2023
Q2 		$253K Buy
888
+7
+0.8% +$2.08K 0.21% 72
2023
Q1 		$245K Buy
881
+43
+5% +$11.9K 0.21% 71
2022
Q4 		$232K Buy
838
+4
+0.5% +$1.13K 0.23% 74
2022
Q3 		$223K Buy
+834
New +$177K 0.24% 68
2021
Q4 		– Sell
-798
Closed -$226K – 97
2021
Q3 		$226K Sell
798
-9
-1% -$2.95K 0.19% 77
2021
Q2 		$279K Sell
807
-12
-1% -$3.63K 0.23% 66
2021
Q1 		$229K Sell
819
-56
-6% -$15.1K 0.2% 74
2020
Q4 		$209K Buy
+875
New +$226K 0.2% 71

Other funds holding BIIB

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $935B AUM
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

LCM Capital Management's BIIB Position: Q3 2024 in Review

LCM Capital Management sold out of Biogen (BIIB) in Q3 2024, closing a stake of 928 shares — an estimated $215K sold.

LCM Capital Management first reported a position in BIIB in Q4 2020 and held it in 11 quarters. The position peaked at $279K in Q2 2021. 917 funds tracked by Wall St. Rank hold BIIB as of Q3 2024.

  • LCM Capital Management reported no remaining Biogen position as of Q3 2024 after selling out during the quarter.
  • LCM Capital Management sold 928 Biogen shares in Q3 2024, an estimated $215K.
  • LCM Capital Management first reported a position in Biogen in Q4 2020 and held it in 11 quarters.
  • LCM Capital Management's Biogen position peaked at $279K in Q2 2021.
  • 917 funds tracked by Wall St. Rank held Biogen as of Q3 2024.

Based on LCM Capital Management's 13F filing for Q3 2024, filed 28 Oct 2024.